This publication reports on newly diagnosed cancers registered in England during 2022. It includes this summary report showing key findings, spreadsheet tables with more detailed estimates, and a methodology document. Cancer registration estimates are provided for: • Incidence of cancer using groupings that incorporate both the location and type of cancer by combinations of gender, age, deprivation, and stage at diagnosis (where appropriate) for England, former Government office regions, Cancer alliances and Integrated care boards • Incidence and mortality (using ICD-10 3-digit codes) by gender and age group for England, former Government office regions, Cancer alliances and Integrated care boards This publication will report on 2022 cancer registrations only, trends will not be reported as the required re-stated populations for 2012 to 2020 are not expected to be published by the Office of National Statistics (ONS) until Winter 2024.

Descriptive statistics for participants included in the genome-wide association studies of lung cancer, coronary heart disease, chronic obstructive pulmonary disease, lung function and heart rate.

Univariable and multivariable Mendelian randomisation IVW and Egger analysis of nicotine exposure proxies (nicotine metabolite ratio, cotinine and cotinine+3’hydroxycotinine) and smoking heaviness (cigarettes per day) and lung cancer.

Details of the inclusion and exclusion of Single Nucleotide Polymorphisms (SNPs) in the analysis exploring the effect of cotinine plus 3’hydroxycotinine (3HC) and smoking heaviness on lung cancer.

Details of the inclusion and exclusion of Single Nucleotide Polymorphisms (SNPs) in the analysis exploring the effect of nicotine metabolite ratio and smoking heaviness on lung cancer.